Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than a dozen years of experience in intellectual property, law and business management. Ms. Donley served as General Counsel and Director of Business Development for WARF for more than eight years. During those eight years, Ms. Donley negotiated hundreds of licenses, sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin.

Gabriela Cezar is a faculty member at the University of Wisconsin—Madison where she pioneered the application of metabolomics to stem cell biology. Her research involves human embryonic stem (hES) cells, cancer stem cells and cells derived from hES cells such as neurons, cardiomyocytes and hepatocyte-like cells. In addition, Dr. Cezar heads the Stem Cell Safety Sciences Lab at UW and is a scientific collaborator with WiCell Research Institute.

Mr. Ferrara began his career with Eli Lilly & Company. In the course of his twenty-year tenure with Lilly, he served in a number of business areas in the United States and Europe. During his last four years at Eli Lilly, he was Corporate Director of New Product Planning and Licensing. His line management experience included the management of pharmaceutical operations, including all aspects of marketing and sales, for both Lilly and Dista in France and a member of the Board of Lilly Industries in the United Kingdom. In May, 1984, Mr. Ferrara co-found Polygen Corporation, a computer software company serving the chemical and pharmaceutical research industries, and initiated a number of research and licensing agreements with academic institutions and major health care corporations in the United States, Europe and Japan. Since founding Boston Healthcare in 1993, he has been involved in the development of a number of companies. Presently he serves on the Boards of Sucampo Pharmaceuticals and Indevus Pharmaceuticals, Inc., both publicly traded companies, and also VelQuest Corporation. In addition, Mr. Ferrara serves on the Board of the Pierce Law Center and is a Member of the Corporation of the Woods Hole Oceanographic Institution. Mr. Ferrara has been a guest speaker at numerous professional meetings and conferences.

Laura Francis leads the finance organization for Promega Corporation, a Madison-based firm which supplies solutions and technical support to the life sciences industry and has revenues exceeding $200 million. She is responsible for planning, analysis, business intelligence and business development for the company. Since Ms. Francis joined Promega in 2004 the company has experienced 40% growth in revenue, 60% growth in profitability, and 85% growth in shareholder value. Ms. Francis was the key driver in three acquisitions that have added to organic revenue growth and profitability.

Dr. Hrusovsky has accumulated over 25 years of diverse experience in general biomedical business management. She has extensive business experience in both diagnostics and pharmaceuticals and has won numerous awards acknowledging her leadership and entrepreneurial skills. Formerly, she served as Vice President of General Medicine/Medical Marketing Strategy/Clinical Operations at GlaxoSmithKline. Dr. Hrusovsky also spent over 20 years at Abbott Laboratories, holding executive management positions in Pharmaceuticals, Clinical Diagnostics, Licensing and Business Development. Dr. Hrusovsky received her Doctor of Medicine degree from the University of British Columbia in Vancouver, as well as a BS in Biochemistry and Genetics..

Andrew Morgan is the Vice President of Quality Operations and Site Manager for Genzyme Corporation’s Middleton, Wisconsin office. He is responsible for the oversight of all product quality control, quality assurance, and compliance activities. He works closely with Genzyme’s Research and Development division to develop an overall drug development quality and regulatory strategy. Mr. Morgan received his pharmacy degree from SWOSU School of Pharmacy in Weatherford, OK. Prior to joining Genzyme he served as the VP of Regulatory, Quality, and Pharmaceutical Sciences at Bone Care International in Middleton, Wisconsin and as the Director of Regulatory Affairs for Celltech Pharmaceuticals, Inc. in Rochester, New York.